Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) in a single patient: A clinicopathologic study of 35 resected cases

被引:21
|
作者
Cao, Jie [1 ]
Huang, Liang [1 ]
Liu, Caifeng [1 ]
Li, Jing [1 ]
Zhang, Xianghua [1 ]
Shen, Jun [1 ]
Li, Jun [1 ]
Lu, Lun [2 ]
Xu, Feng [1 ]
Yan, Jianjun [1 ]
Wu, Mengchao [1 ]
Lau, Wan Yee [1 ,3 ]
Yan, Yiqun [1 ]
机构
[1] Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 1, Shanghai 200438, Peoples R China
[2] Eastern Hepatobiliary Surg Hosp, Dept Radiol, Shanghai 200438, Peoples R China
[3] Chinese Univ Hong Kong, Fac Med, Shatin, Hong Kong, Peoples R China
关键词
clinicopathologic characteristics; double hepatic cancer; hepatocellular carcinoma; intrahepatic cholangiocarcinoma; prognosis; VIRUS-RELATED CIRRHOSIS; CHOLANGIOCELLULAR CARCINOMA; PREDICTIVE FACTORS; SURGICAL-TREATMENT; RISK-FACTORS; LIVER; RECURRENCE; SURVIVAL; FEATURES;
D O I
10.1111/jgh.12143
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aim Combined hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) coexisting in the liver have rarely been reported before. The aim of this study is to report on the clinicopathological features and prognosis of patients with double hepatic cancer. Methods The clinicopathologic, perioperative, and long-term survival data of 35 patients who underwent synchronously resection of double hepatic cancer from January 2002 to December 2008 were studied retrospectively. The data were compared with those patients who had pure HCC or ICC during the study period. Results The incidence of double hepatic cancer was 0.25%. The male to female ratio was 4:1. The prevalence of hepatitis B infection was very high (35/35). Simultaneously elevated serum -fetoprotein and cancer antigen 19-9 levels (10/35) were observed in 10/35 patients. Metastatic lymph nodes with ICC cells were diagnosed in 4 of 35 patients. Only one patient was diagnosed preoperatively with double hepatic cancer of HCC and ICC. The median overall survival (OS) was 18 months, and the 1-year, 3-year, and 5-year OS rates were 60.0%, 28.9%, and 23.1%, respectively. Multivariate analysis indicated that the tumor size of ICC, presence of lymph node metastasis, and histological differentiation of the ICC component were independent risk factors of OS. Conclusion Double hepatic cancer of HCC and ICC is very rare with distinctive clinicopathologic features. The prognosis of double hepatic cancer was as poor as pure ICC. The ICC component played a more important role than the HCC component in influencing the prognosis of double hepatic cancer.
引用
收藏
页码:1025 / 1031
页数:7
相关论文
共 50 条
  • [31] Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?
    Qiang Zhou
    Hao Cai
    Ming-Hao Xu
    Yao Ye
    Xiao-Long Li
    Guo-Ming Shi
    Cheng Huang
    Xiao-Dong Zhu
    Jia-Bin Cai
    Jian Zhou
    Jia Fan
    Yuan Ji
    Hui-Chuan Sun
    Ying-Hao Shen
    Hepatobiliary&PancreaticDiseasesInternational, 2021, 20 (01) : 13 - 20
  • [32] Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?
    Zhou, Qiang
    Cai, Hao
    Xu, Ming-Hao
    Ye, Yao
    Li, Xiao-Long
    Shi, Guo-Ming
    Huang, Cheng
    Zhu, Xiao-Dong
    Cai, Jia-Bin
    Zhou, Jian
    Fan, Jia
    Ji, Yuan
    Sun, Hui-Chuan
    Shen, Ying-Hao
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2021, 20 (01) : 13 - 20
  • [33] Clinicopathologic and Molecular Characteristics of Resected Primary Poorly Differentiated Thyroid Carcinoma (PDTC): A Single-Institution Retrospective Study of 364 Cases
    Xu, Bin
    Dogan, Snjezana
    Katabi, Nora
    Saliba, Maelle
    Khimraj, Anjanie
    Fagin, James
    Ghossein, Ronald
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 377 - 378
  • [34] Clinicopathologic and Molecular Characteristics of Resected Primary Poorly Differentiated Thyroid Carcinoma (PDTC): A Single-Institution Retrospective Study of 364 Cases
    Xu, Bin
    Dogan, Snjezana
    Katabi, Nora
    Saliba, Maelle
    Khimraj, Anjanie
    Fagin, James
    Ghossein, Ronald
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 377 - 378
  • [35] Synchronous double primary hepatic cancer consisting of hepatocellular carcinoma and cholangiolocellular carcinoma: A case report
    Yamamoto M.
    Oshita A.
    Nishisaka T.
    Nakahara H.
    Itamoto T.
    Journal of Medical Case Reports, 12 (1)
  • [36] HEPATOCELLULAR-CARCINOMA AFTER TRANSCATHETER HEPATIC ARTERIAL EMBOLIZATION - A HISTOPATHOLOGIC STUDY OF 84 RESECTED CASES
    HIGUCHI, T
    KIKUCHI, M
    OKAZAKI, A
    CANCER, 1994, 73 (09) : 2259 - 2267
  • [37] Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Yamauchi, Yurika
    Saeki, Issei
    Yamasaki, Takahiro
    Egusa, Maho
    Nishiyama, Natsuko
    Fujioka, Tsuyoshi
    Kawamoto, Daiki
    Nishimura, Tatsuro
    Tanabe, Norikazu
    Oono, Takashi
    Matsumoto, Toshihiko
    Ishikawa, Tsuyoshi
    Marumoto, Yoshio
    Matsukuma, Satoshi
    Shindo, Yoshitaro
    Tokumitsu, Yukio
    Yoshimine, Sota
    Murakami, Junichi
    Tanaka, Toshiki
    Kimura, Sotai
    Hoshii, Yoshinobu
    Hamano, Kimikazu
    Nagano, Hiroaki
    Takami, Taro
    HEPATOLOGY RESEARCH, 2023, 53 (07) : 681 - 686
  • [38] Optimizing the Tumor Staging Criteria for Hepatocellular Carcinoma: A Clinicopathologic Study of 106 Cases at a Single Institution
    Zhang, Dongwei
    Liao, Xiaoyan
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 993 - 994
  • [39] Optimizing the Tumor Staging Criteria for Hepatocellular Carcinoma: A Clinicopathologic Study of 106 Cases at a Single Institution
    Zhang, Dongwei
    Liao, Xiaoyan
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 993 - 994
  • [40] Primary hepatic neuroendocrine carcinoma: clinicopathologic analysis of surgical treatment of 12 cases from a single institutional experience
    Li, Jiaxin
    Zhang, Hanzhi
    Chen, Kefei
    Zeng, Yong
    Chen, Zheyu
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (01): : 1414 - 1419